Haemonetics Corporation (NYSE:HAE) currently supplies 1.8 million in-line whole blood collection kits to The American Red Cross annually; approximately 0.4 million such kits include Haemonetics’ Acrodose platelet pooling product and were not included in the tender.The remaining 1.4 million kits will begin to be sourced from a competitor commencing early in fiscal 2015. Annual revenues approximating $25 million in fiscal 2014 will be impacted going forward.The Company expects that, after appropriate variable cost reductions, earnings per share will be negatively impacted by approximately $0.15 annually upon transition of this business to the competitor. Haemonetics Corporation (NYSE:HAE) shares after opening at $35.35 moved to $35.92 on last trade day and at the end of the day closed at $33.61. Company price to sales ratio in past twelve months was calculated as 1.84 and price to cash ratio as 9.78. Haemonetics Corporation (NYSE:HAE) showed a negative weekly performance of -9.19%.
Palatin Technologies, Inc. (NYSEMKT:PTN) is one of those rare cases where the message deserves to be delivered again, as there’s still a lot of opportunity left for newcomers to tap into. Palatin Technologies, Inc. (NYSEMKT:PTN) shares fell -10.42% in last trading session and ended the day on $1.29. PTN return on equity ratio is recorded as -59.10% and its return on assets is -53.20%.Palatin Technologies, Inc. (NYSEMKT:PTN) yearly performance is 111.48%.
STAAR Surgical Company (NASDAQ:STAA) was upgraded by research analysts at William Blair from a “market perform” rating to an “outperform” rating in a report released on Monday, Analyst Ratings Net reports. STAAR Surgical Company (NASDAQ:STAA) shares moved up 5.90% in last trading session and was closed at $17.59, while trading in range of $16.90-$17.74. STAAR Surgical Company (NASDAQ:STAA) year to date performance is 8.65%.
On Mar4, 2014 Trinity Biotech plc (Nasdaq:TRIB) announced results for fiscal year 2013 and the quarter ended December 31, 2013.Fiscal year 2013 Results, Total revenues for fiscal year 2013 were $91.2m versus $82.5m in 2012, thus representing an increase of 10.6% year on year.Point-of-care revenues increased by over 3% from $19.2m in 2012 to $19.8m in 2013. This growth was due to the continuing strength of HIV sales in Africa. Trinity Biotech plc (ADR) (NASDAQ:TRIB) weekly performance is -10.78%. On last trading day company shares ended up $24.24. Trinity Biotech plc (ADR) (NASDAQ:TRIB) distance from 50-day simple moving average is -8.84%. Analysts mean target price for the company is $32.75.